Linked Data API

Show Search Form

Search Results

1138888
registered interest false more like this
date less than 2019-07-15more like thismore than 2019-07-15
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Sickle Cell Diseases: Health Services remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313 on Sickle Cell Diseases, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for people with sickle cell disease; and what the per capita annual cost is of providing each of those services. more like this
tabling member constituency Kingston upon Hull North more like this
tabling member printed
Diana Johnson remove filter
uin 277137 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-19more like thismore than 2019-07-19
answer text <p>NHS England commissions specialised services for people living with sickle cell disease. These services are part of the specialised haemoglobinopathy services commissioned by NHS England across the country. NHS England spends over £60 million on sickle cell disease within these services annually - £60.4 million in 2017/18. Information about the services provided by individual clinical commissioning groups or other public bodies is not collected or held centrally.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-19T09:46:21.973Zmore like thismore than 2019-07-19T09:46:21.973Z
answering member
4455
label Biography information for Seema Kennedy more like this
previous answer version
129855
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1533
label Biography information for Diana Johnson more like this
1138889
registered interest false more like this
date less than 2019-07-15more like thismore than 2019-07-15
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Sickle Cell Diseases: Health Services remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for sickle cell disease patients with (i) stroke, (ii) chronic kidney disease, (iii) end-stage renal disease and (iv) pulmonary hypertension; and what the annual per capita cost is of providing each of those services. more like this
tabling member constituency Kingston upon Hull North more like this
tabling member printed
Diana Johnson remove filter
uin 277138 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-19more like thismore than 2019-07-19
answer text <p>NHS England does not commission separate services for sickle cell patients with stroke, chronic kidney disease, end-stage renal disease or pulmonary hypertension and so cannot provide annual per capita costs. These services are commissioned on behalf of all patients that require them, which would include people living with sickle cell disease.</p><p>NHS England has recently undertaken a review of haemoglobinopathy services to ensure that patients living with conditions such as sickle cell disease are able to access the high-quality services they need for their condition across the country. NHS England is now commissioning a networked-based model of care for specialised haemoglobinopathy services which will included specialist haemoglobinopathy teams across the country, regional haemoglobinopathy coordination centres and a National Haemoglobinopathy Panel. The new model will enable advice to be provided to local clinicians on the management of patients with sickle cell disease 24 hours a day, seven days a week. Haemoglobinopathy coordination centres will organise and run networks for sickle cell disease, providing leadership and education for local services.</p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-19T09:45:39.337Zmore like thismore than 2019-07-19T09:45:39.337Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1533
label Biography information for Diana Johnson more like this
1128812
registered interest false more like this
date less than 2019-06-03more like thismore than 2019-06-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Sickle Cell Diseases: Health Services remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of potential levels of inequality in (a) the life expectancy and (b) NHS service provision for patients with sickle cell disease compared to other NHS patients. more like this
tabling member constituency Kingston upon Hull North more like this
tabling member printed
Diana Johnson remove filter
uin 259466 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-06more like thismore than 2019-06-06
answer text <p>Evidence suggests that life expectancy for people with sickle cell disease is improving. This is due to a number of factors including:</p><p>- Improved newborn screening coverage to enable earlier diagnosis;</p><p>- Use of the National Haemoglobinopathy Registry to monitor individuals’ health, treatment and their annual reviews;</p><p>- Access to specific diagnostics and medication, such as hydroxyurea; and</p><p>- A Commissioning for Quality and Innovation (CQUIN) incentive has been in place for the last two years to improve access to apheresis for individuals with sickle cell disease.</p><p>All these factors are reflected in the service specification quality indicators which providers are required to report against so that implementation can be monitored.</p><p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live. The equality impact assessment on the new service model indicates that it will advance the promotion of equality and support the further reduction of health inequalities. This will be through ensuring that patients with thalassemia and sickle cell conditions have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live. These centres will promote best practice in service delivery.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-06T13:13:01.52Zmore like thismore than 2019-06-06T13:13:01.52Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1533
label Biography information for Diana Johnson more like this
1127755
registered interest false more like this
date less than 2019-05-21more like thismore than 2019-05-21
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Sickle Cell Diseases: Health Services remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS England’s planned restructuring of haemoglobinopathy services on (a) equitable access to services, (b) access to the most effective treatments, (c) access to highly specialised care and (d) quality of care in community-based settings for patients with sickle cell disease. more like this
tabling member constituency Kingston upon Hull North more like this
tabling member printed
Diana Johnson remove filter
uin 256973 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-04more like thismore than 2019-06-04
answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN
256972 more like this
256974 more like this
257011 more like this
question first answered
less than 2019-06-04T16:13:21.707Zmore like thismore than 2019-06-04T16:13:21.707Z
answering member
4455
label Biography information for Seema Kennedy more like this
attachment
1
file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx more like this
title FAE sickle cell NHS England table more like this
tabling member
1533
label Biography information for Diana Johnson more like this
1127756
registered interest false more like this
date less than 2019-05-21more like thismore than 2019-05-21
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Sickle Cell Diseases: Health Services remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will publish impact assessments of the potential effects of NHS England’s planned restructuring of haemoglobinopathy services on treatment of (a) all haemoglobinopathies and (b) sickle cell disease. more like this
tabling member constituency Kingston upon Hull North more like this
tabling member printed
Diana Johnson remove filter
uin 256974 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-04more like thismore than 2019-06-04
answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
grouped question UIN
256972 more like this
256973 more like this
257011 more like this
question first answered
less than 2019-06-04T16:13:21.767Zmore like thismore than 2019-06-04T16:13:21.767Z
answering member
4455
label Biography information for Seema Kennedy more like this
attachment
1
file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx more like this
title FAE sickle cell NHS England table more like this
tabling member
1533
label Biography information for Diana Johnson more like this